Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 139 Breast Neoplasms 31 Prostatic Neoplasms 29 Insulin Resistance 28 Obesity 19 Pancreatic Neoplasms 13 Neoplasms 12 Infertility 12 Endometrial Neoplasms 12 Carcinoma, Non-Small-Cell Lung 12 Colorectal Neoplasms 11 Anovulation 9 Lung Neoplasms 8 Metabolic Syndrome 7 Melanoma 7 Hyperandrogenism 7 Glioblastoma 7 Diabetes Mellitus 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Rectal Neoplasms 5 Adenocarcinoma 5 Weight Loss 4 Urinary Bladder Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Head and Neck Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Adenocarcinoma of Lung 4 Uterine Cervical Neoplasms 3 Recurrence 3

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × pCR Rate × Metformin × Clear all

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡